Bioventus Inc.
BVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | 0.55 | -0.00 | -0.25 |
| FCF Yield | 5.51% | 2.42% | -9.37% | 0.32% |
| EV / EBITDA | 24.99 | -29.82 | -4.51 | 21.39 |
| Quality | ||||
| ROIC | -1.96% | -12.32% | -11.62% | 1.13% |
| Gross Margin | 67.72% | 64.06% | 64.65% | 70.25% |
| Cash Conversion Ratio | -122.00 | -0.13 | 0.09 | 2.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.83% | 5.94% | 16.83% | 7,552,992.90% |
| Free Cash Flow Growth | 373.43% | 153.16% | -814.66% | -95.89% |
| Safety | ||||
| Net Debt / EBITDA | 7.50 | -15.51 | -3.19 | 6.90 |
| Interest Coverage | -0.31 | -2.01 | -13.91 | 10.85 |
| Efficiency | ||||
| Inventory Turnover | 2.00 | 2.02 | 2.14 | 2.08 |
| Cash Conversion Cycle | 216.78 | 222.84 | 194.06 | 233.33 |